Claudia Schneider

Title: Claudia Schneider: Innovator in Cancer Treatment

Introduction

Claudia Schneider is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for cancer. Her innovative work has led to the filing of a patent that showcases her expertise and dedication to improving patient outcomes.

Latest Patents

Claudia Schneider holds a patent for the "Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines." This invention relates to the use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or a pharmaceutical composition containing it, as a sole active agent or in combination with other active agents for the preparation of a medicament aimed at treating or preventing cancer. The patent also covers the use of biomarkers involved in the modification of Bel expression, HER family expression, and PIK3CA signaling, which can predict a cancer patient's sensitivity or resistance to the compound.

Career Highlights

Claudia Schneider is associated with Bayer Intellectual Property GmbH, where she continues to advance her research and development efforts. Her work is characterized by a strong focus on innovative solutions for complex medical challenges, particularly in oncology.

Collaborations

Claudia collaborates with Ningshu Liu, enhancing her research capabilities and broadening the impact of her inventions in the medical field.

Conclusion

Claudia Schneider's contributions to cancer treatment through her innovative patent demonstrate her commitment to advancing medical science. Her work not only reflects her expertise but also holds the potential to significantly improve patient care in oncology.